Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Snapshot

The role of the hepatic autonomic nervous system

Qiankun Luo, Pan Liu, Yifei Dong, Tao Qin

Clin Mol Hepatol. 2023;29(4):1052-1055. Published online July 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0244

View: 849 Download: 40

Correspondence

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):1050-1051. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0310

View: 660 Download: 20

Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):1048-1049. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0261

View: 946 Download: 24

Letter to the Editor

Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh

Clin Mol Hepatol. 2023;29(4):1046-1047. Published online August 22, 2023

DOI: https://doi.org/10.3350/cmh.2023.0268

View: 768 Download: 29 Citation: 1

Letter regarding “Evidence-based hyponatremia management in liver disease”

Daphne J. Theodorou, Stavroula J. Theodorou, Ioannis V. Mitselos

Clin Mol Hepatol. 2023;29(4):1043-1045. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0204

View: 874 Download: 27 Citation: 1

Original Article

Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection

Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon

Clin Mol Hepatol. 2023;29(4):1029-1042. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0190

View: 1163 Download: 64

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis

Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim

Clin Mol Hepatol. 2023;29(4):1013-1028. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0131

View: 1536 Download: 94 Citation: 1

Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study

Vy H. Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(4):1002-1012. Published online September 11, 2023

DOI: https://doi.org/10.3350/cmh.2023.0205

View: 1199 Download: 71

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe

Clin Mol Hepatol. 2023;29(4):987-1001. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0035

View: 1983 Download: 196 Citations: 4

Editorial

Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?

Hyo-Cheol Kim

Clin Mol Hepatol. 2023;29(4):984-986. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0275

View: 817 Download: 25

Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?

Eugene Han, Yong-ho Lee

Clin Mol Hepatol. 2023;29(4):980-983. Published online August 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0250

View: 820 Download: 62

Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy

Sang Min Yoon

Clin Mol Hepatol. 2023;29(4):977-979. Published online August 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0336

View: 577 Download: 33

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0367

View: 739 Download: 42

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 926 Download: 111

Review

Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma

Sung Uk Lee, Tae Hyun Kim

Clin Mol Hepatol. 2023;29(4):958-968. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0274

View: 1077 Download: 55 Citation: 1

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma

Hwa Kyung Byun, Changhwan Kim, Jinsil Seong

Clin Mol Hepatol. 2023;29(4):945-957. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0217

View: 1183 Download: 60 Citations: 2

Evidence-based hyponatremia management in liver disease

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):924-944. Published online June 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0090

View: 1791 Download: 182 Citations: 3

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(4):909-923. Published online May 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0114

View: 1600 Download: 196 Citation: 1

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung, Jai Won Chang

Clin Mol Hepatol. 2023;29(4):891-908. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0024

View: 4429 Download: 1,107 Citation: 1

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 1757 Download: 141 Citations: 3

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka

Clin Mol Hepatol. 2023;29(4):851-868. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0434

View: 5460 Download: 286 Citation: 1

Special Review

Waiting for the changes after the adoption of steatotic liver disease

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):844-850. Published online September 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0291

View: 1040 Download: 129

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0277

View: 1879 Download: 239 Citations: 3

Erratum

Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]

Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong

Clin Mol Hepatol. 2023;29(3):830-830. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0345e
Corrects: Clin Mol Hepatol 2023;29(2):496

View: 1135 Download: 19

Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(3):828-829. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054e
Corrects: Clin Mol Hepatol 2023;29(2):367

View: 1027 Download: 19

Snapshot

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?

Soon Kyu Lee, Jung Hyun Kwon

Clin Mol Hepatol. 2023;29(3):825-827. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0185

View: 1366 Download: 70

Correspondence

Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng

Clin Mol Hepatol. 2023;29(3):823-824. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0182

View: 1323 Download: 37 Citation: 1

Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng

Clin Mol Hepatol. 2023;29(3):821-822. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0183

View: 1306 Download: 63 Citation: 1

Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(3):820-820. Published online May 19, 2023

DOI: https://doi.org/10.3350/cmh.2023.0135

View: 1103 Download: 26

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

View: 1224 Download: 38

Viewed By 4787	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4753	Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Viewed By 3765	MAFLD: How is it different from NAFLD?
Viewed By 2613	Management of refractory ascites
Viewed By 2455	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 131	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 78	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 60	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 55	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 54	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Article category